CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Inhalerx Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Inhalerx Ltd
Level 5, 126 Phillip Street
Phone: +61 383955446p:+61 383955446 SYDNEY, NSW  2000  Australia Ticker: LSHLSH
Business Summary
InhaleRx Limited is an Australia-based healthcare company. The Company is focused on developing medicinal drug-device products to address unmet medical needs in the pain management and mental health sectors. It is engaged in the development of precision medicine delivered through inhalation. The Company is focused on the development of innovative inhaled therapeutics. The Company’s novel drug device combinations target the treatment of breakthrough cancer pain (BTcP) (IRX211) and panic disorder (PD)(IRX611a), with the objective of helping to improve the quality of life of BTcP and PD sufferers. IRX211 is a THC based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering with acute episodic bursts of breakthrough pain. It holds an approved innovation patent and has lodged an Australian provisional patent application for the treatment of BTcP with the Australian Patent Office.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board SeanWilliams 7/26/2021 7/26/2021
Chief Executive Officer DarrylDavies 9/27/2022 7/20/2021
Chief Scientific Officer RobJenny 9/27/2022 9/27/2022
Company Secretary, Director JamesBarrie 3/1/2024 8/3/2023
Non-Executive Director RonaldWise 11/27/2024 11/27/2024

Business Names
Business Name
IRX
LSH

General Information
Outstanding Shares: 189,766,957 (As of 6/30/2024)
Shareholders: 575
Stock Exchange: ASX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025